Latest Blueprint Medicines News & Updates

See the latest news and media coverage for Blueprint Medicines. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Blueprint Medicines

Biopharmaceutical company developing medicines for mast cell diseases and cancer

blueprintmedicines.com
Headquarters
Cambridge, United States
Founded year
2011
Company type
Public company
Number of employees
600–1,000
Industry
Pharmaceuticals

Last updated

Latest news about Blueprint Medicines

In short: Blueprint Medicines was acquired by Sanofi for $9.1 billion, leading to job cuts and the integration of its immunology drug portfolio.

Company announcements

Blueprint Medicines

Blueprint Medicines announces AYVAKIT data at EHA and EAACI

Data from PIONEER, PATHFINDER, and EXPLORER trials reinforce sustained efficacy and safety in systemic mastocytosis treatment. Presentations include oral and flash talks.

Unlock all announcements with a

Media coverage

European Pharmaceutical Review

Blueprint’s rare disease drug Ayvakit shows long-term benefit

New four-year clinical data from Blueprint Medicines, a Sanofi company, show that Ayvakit (avapritinib) enabled sustained symptom control in patients with the rare disease indolent...

Unlock all articles with a

Never miss news about Blueprint Medicines

Track Blueprint Medicines and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Blueprint Medicines competitors & trending companies

Browse news for competitors to Blueprint Medicines and other trending companies.